Market Scenario
A Glioma is a type of tumor that
originates in the brain and is also known as a primary brain tumor. There are
numerous types of gliomas which are entitled based on the origin of the cell
type including oligodendrogliomas, astrocytoma, ependymomas, and glioblastoma.
Nearly 33 percent of all brain tumors are gliomas. These originate in glial
cells surrounding the neurons in the brain.
Global Glioma Diagnosis and Treatment
market is expected to grow at a CAGR of approximately
10.1% during the forecast period, 2017–2023.
According to the American Brain
Tumor Association, more than 79,000 new cases of primary brain tumors were
diagnosed in 2017 with 24.7% of those being gliomas.
Brain tumors are one
of the prominent causes of cancer among children and teenagers. Glioma is the
most common type of brain tumor which accounts for approximately half of all
the astrocytoma. The increasing occurrence of glioblastoma over the years is
responsible for the growth of the glioma diagnosis and treatment market. The
upcoming drug launches and developments in research are instrumental for the
growth of the market. In addition, the current unmet need is expected to drive
the gliomas industry over the forecast period. Changing financial demands and
access to healthcare facilities are some of the factors that are constraining
the market growth.
Astrocytoma is the most common
types of glioma diagnosed worldwide, as more than 30% of all the diagnosed
cases with brain tumors are astrocytoma. These types of tumors are not curable
as they spread easily through normal brain tissue. The American Brain Tumor
Association has evaluated that around 7% of all the primary brain tumors
represent astrocytoma.
The expanding market for the
treatment of brain cancer-associated symptoms, the increasing prevalence of
brain cancer, and innovations in drug delivery to brain cancer cells are some
of the key factors augmenting the demand in the global glioma diagnosis and
treatment market. Furthermore, the introduction of novel therapies coupled with
various organizations generating awareness and increasing geriatric population
are factors driving the growth of the global glioma diagnosis and treatment
market.
Key Players
Some of the key players in the global
glioma diagnosis and treatment market are Thermo Fisher Scientific Inc. (U.S.),
Emcure Pharmaceuticals Ltd. (India), Sigma-Aldrich Co. (U.S.), Pfizer Inc.
(U.S.), Taj Pharmaceuticals Limited (India), Novartis International AG
(Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), GE Healthcare
(U.S.), Siemens Healthineers (U.S.), Philips Healthcare (U.S.), Shimadzu
Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Merck &
Co., Inc. (U.S.), F. Hoffmann-Le Roche AG (Switerland), Arbor Pharmaceuticals,
LLC (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Amneal
Pharmaceuticals. LLC (U.S.), AstraZeneca (UK), Carestream Health (U.S.),
Hitachi Medical Corporation (U.S.), and others.
Segmentation
Geographically, the Americas glioma
diagnosis and treatment market is segmented into two major regions, namely,
North America and South America.
North America accounted for the largest
share of the global gliomas industry in 2016, and the trend is expected to continue
over the projected period. Moreover, it is anticipated that about 80,000 new
cases will be registered related to brain tumors in the year 2017 which
includes 26,000 primary malignant brain tumors.
The Americas glioma diagnosis and
treatment market is segmented on the basis of type, diagnosis, treatment,
grade, location, and end-user.
Regional Analysis
The global glioma diagnosis and
treatment market consist of four major regions, namely, the Americas, Europe,
Asia Pacific, and the Middle East and Africa.
Growing medical tourism and
prevalence of metastatic tumors that require surgical procedures are favoring
the growth of the market in the Middle East and Africa. In addition, the
development of drug delivery technologies, a combination of modern diagnostic
techniques, and increasing awareness of various types of brain tumors are
similarly supporting the growth of this market.
The Americas dominates the market
owing to the key players domiciled in these regions coupled with the increasing
incidences of brain tumor, rising awareness among people, and increasing
healthcare expenditure. Brain tumor is the third most common types of cancer in
adults in North America. According to the North American Brain Tumor Coalition
over 44,500 people in the U.S. were diagnosed with a primary tumor in the brain
in 2014. Thus, the increasing incidences of primary brain tumor support the
growth of the malignant glioma treatment in North America.
Asia Pacific is estimated to be the
most lucrative market for gliomas due to the increasing occurrence of brain
tumors in Asia Pacific countries such as China and others. The growth in the
Asian market is fueled by the expanding healthcare infrastructure and presence
of untapped market opportunities in this region. This region is considered as
an emerging market owing to the increasing number of manufacturers coupled with
the increasing market penetration.
Browse More Details
of the Report @ https://www.marketresearchfuture.com/reports/glioma-diagnosis-treatment-market-5877
No comments:
Post a Comment